For research use only. Not for therapeutic Use.
PI3K-IN-1 (XL-147 derivative 1) is a potent inhibitor of PI3K. PI3K-IN-1 (25 μM) blocks PI3K/Akt signaling pathways[1].
PI3K-IN-1 (25 μM) blocks PI3K/Akt signaling pathways. By using the PI3K inhibitor PI3K-IN-1, TGF-β1 induced transformation into myofibroblast is also inhibited, with relatively reduced expressions of α-SMA, Col-1 and Timp-1[1].
| Catalog Number | I001342 |
| CAS Number | 1349796-36-6 |
| Synonyms | N-[4-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide |
| Molecular Formula | C31H29N5O6S |
| Purity | ≥95% |
| InChI | InChI=1S/C31H29N5O6S/c1-19-9-10-20(15-28(19)42-4)31(37)33-21-11-13-25(14-12-21)43(38,39)36-30-29(34-26-7-5-6-8-27(26)35-30)32-22-16-23(40-2)18-24(17-22)41-3/h5-18H,1-4H3,(H,32,34)(H,33,37)(H,35,36) |
| InChIKey | HJSSPYJVWLTYHG-UHFFFAOYSA-N |
| SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC3=NC4=CC=CC=C4N=C3NC5=CC(=CC(=C5)OC)OC)OC |
| Reference | [1]. Mingyu Hao, et al. Exploring the Role of SRC in Extraocular Muscle Fibrosis of the Graves’ Ophthalmopathy. Front Bioeng Biotechnol. 2020 May 8;8:392. |
